Mesothelioma And Alimta
EDM number 2610 in 2005-06, proposed by Fraser Kemp on 19/07/2006.
That this House regrets that the National Institute for Health and Clinical Excellence (NICE) Final Appraisal Determination on Alimta does not recommend Alimta for the treatment of mesothelioma except as part of ongoing or new clinical trials; notes that in December 2005 the Northern Cancer Network said mesothelioma patients in the North East would be able to get the drug and that that decision is now in question; further notes that many trials of Alimta have shown it is successful in increasing life expectancy and improving the quality of life of patients; further notes the high industrial use of asbestos in the North East area such as at the Turner and Newell factories, and throughout the United Kingdom, which is associated with mesothelioma; further notes that NHS patients with mesothelioma face paying up to £24,000 at a private hospital for the drug, which can extend the lives of sufferers by up to three months; would welcome the Secretary of State for Health's intervention in this matter; and calls on NICE to reconsider its decision.
This motion has been signed by a total of 61 MPs.
Download raw data as csv or xml.